title: Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.
abstract: BACKGROUND
  Vascular calcification has detrimental consequences on chronic kidney disease (CKD) patients, yet its pathogenesis is not fully understood. Fibroblast growth factor-23 (FGF-23) is involved in the regulation of mineral metabolism which may in turn affect vascular calcification. Data on the relationship between FGF-23 and peripheral vascular calcification, using conventional radiographs, are conflicting, and less is known about its relation to aortic calcification. We conducted this study to investigate the relationship between FGF-23 and aortic calcification in a standard haemodialysis setting.
  
  
  METHODS
  The study included 65 haemodialysis patients (46 prevalent and 19 incident) on a three times 4-h dialysis schedule as well as 15 controls. Those with diabetes, oral anticoagulation or parathyroidectomy were excluded. Intact FGF-23, parathormone, lipids, calcium and phosphorus were measured. Aortic calcification index (ACI) was assessed by a non-contrast computerized tomography (CT) of the abdominal aorta.
  
  
  RESULTS
  FGF-23 levels were higher among haemodialysis patients (4681.3 +/- 3906.1 pg/mL) compared to controls (98.2 +/- 51.9 pg/mL), P = 0.005. ACI was higher in haemodialysis patients (14.1 +/- 12) than controls (3.2 +/- 3.6), P = 0.009. FGF-23 (P < 0.0001) and systolic blood pressure (BP) (P < 0.0001) were independently related to ACI in stepwise multiple regression analysis of pooled analysis of haemodialysis patients, R(2) = 0.476; in subgroup analysis, the independent factors relating to ACI among prevalent dialysis patients were systolic BP (P < 0.0001), FGF-23 (P = 0.002) and age (P = 0.012), R(2)=0.48; whereas in incident patients, only FGF-23 was associated with ACI (P = 0.007), R(2) = 0.37.
  
  
  CONCLUSIONS
  In haemodialysis patients, FGF-23 and ACI were significantly increased, and FGF-23 was independently associated with aortic calcification.
authors.affiliation: Department of Nephrology, School of Medicine, Kasr El-Aini School of Medicine, Cairo University, Cairo, Egypt.
authors.forename: Mohamed M
authors.initials: MM
authors.lastname: Nasrallah
authors.forename: Amal R
authors.initials: AR
authors.lastname: El-Shehaby
authors.forename: Mona M
authors.initials: MM
authors.lastname: Salem
authors.forename: Noha A
authors.initials: NA
authors.lastname: Osman
authors.forename: Esam
authors.initials: E
authors.lastname: El Sheikh
authors.forename: Usama A A
authors.initials: UA
authors.lastname: Sharaf El Din
mesh_terms: D000328:Adult; D000368:Aged; D001012:Aorta, Abdominal / Q000000981:diagnostic imaging; D001018:Aortic Diseases / Q000097:blood* / Q000453:epidemiology*; D002114:Calcinosis / Q000097:blood* / Q000453:epidemiology*; D016022:Case-Control Studies; D002908:Chronic Disease; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015995:Prevalence; D012044:Regression Analysis; D006435:Renal Dialysis; D012307:Risk Factors; D014057:Tomography, X-Ray Computed
chemical_list: C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23